Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedMedullary thyroid carcinoma is now listed as a condition, and the Genetic and Rare Diseases Information Center has been added to the Resources section.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision: v3.4.3 is shown instead of v3.4.2. There are no visible changes to the study information or user actions on the page.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-status notice and the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check69 days agoChange DetectedA site-wide funding/status notice was added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check76 days agoChange DetectedUpdates are limited to UI and metadata changes: glossary display toggle, updated QC status wording, No FEAR Act Data label, and a new Revision: v3.4.0 replacing v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.